Первая клетка. И чего стоит борьба с раком до последнего - Азра Раза

Davis D. The Secret History of the War on Cancer. New York: Basic Books, 2007.

Scannell J. W. et al. Diagnosing the Decline in Pharmaceutical R&D Efficiency. Nature Reviews Drug Discovery. 11 (2012): 191–200.

Chandrasekar Th. Why Are We Losing the War on Cancer? 2018 European Society for Medical Oncology Congress (#ESMO18), October 19–23, 2018, Munich, Germany. www.urotoday.com/conference-highlights/esmo-2018/esmo-2018-prostate-cancer/107789-esmo-2018-why-we-are-losing-the-war-on-cancer.html

Ehrenreich B. Bright-Sided: How the Relentless Promotion of Positive Thinking Has Undermined America. New York: Metropolitan Books, 2009.

Baldwin J. Letter from a Region in My Mind. New Yorker, November 9, 1962.

DÖhne H. et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel. Blood. 129 (2017): 424–447.

LeBlanc Th. W., Erba H. P. Shifting Paradigms in the Treatment of Older Adults with AML. Seminars in Hematology. 56, no. 2 (2019): 110–117.

Goldman J. M. Chronic Myeloid Leukemia: A Historical Perspective. Seminars in Hematology. 47, no. 4 (2010): 302–311.

Lo-Coco F., Cicconi L. History of Acute Promyelocytic Leukemia: A Tale of Endless Revolution. Mediterranean Journal of Hematology and Infectious Diseases. 3, no. 1 (2011): e2011067.

Mak I. W. et al. Lost in Translation: Animal Models and Clinical Trials in Cancer Treatment. American Journal of Translational Research. 6, no. 2 (2014): 114–118.

Wong Ch. H. et al. Estimation of Clinical Trial Success Rates and Related Parameters. Biostatistics. 20, no. 2 (2019): 273–286.

Lowe D. A New Look at Clinical Success Rates. Science Translational Medicine, February 2, 2018. https://blogs.sciencemag.org/pipeline/archives/2018/02/02/a-new-look-at-clinical-success-rates

Nixon N. A. Drug Development for Breast, Colorectal, and Non-Small Cell Lung Cancers from 1979 to 2014. Cancer. 123, no. 23 (2017): 4672–4679.

Hay M. et al. Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology. 32 (2014): 40–51.

95 % of Promising Cancer Research Fails. Dying for a Cure, July 10, 2016.

http://dyingforacure.org/blogs/95-promising-cancer-research-fails/

Davis C. et al. Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009–13. BMJ. (2017): 359.

Kola I., Landis J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery. 3 (2004): 711–716.

Hay M. et al. Clinical Development Success Rates for Investigational Drugs. Nature Biotechnology. 32, no. 1 (2014): 40–51.

Thomas D. W. et al. Clinical Development Success Rates, 2006–2015.

www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006–2015 %20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

Siegel R. L. et al. Cancer Statistics 2018. CA. 68, no. 1 (2018): 7–30.

Siegel R. L. et al. Cancer Statistics 2019. CA. 69, no. 1 (2019): 7–34.

Cancer Death Rates Vary Greatly Among US Counties. American Cancer Society. www.cancer.org/latest-news/cancer-death-rates-vary-greatly-among-us-counties.html

Mokdad A. H. et al. Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980–2014. JAMA. 317, no. 4 (2017): 388–406.

Maeda H., Khatami M. Analyses of Repeated Failures in Cancer Therapy for Solid Tumors: Poor Tumor-Selective Drug Delivery, Low Therapeutic Efficacy and Unsustainable Costs. Clinical and Translational Medicine. 7, no. 1 (2018): 11.

Fojo T., Grady C. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $ 440 Billion Question. Journal of the National Cancer Institute. 101, no. 15 (2009): 1044–1049.

Kantarjian Hagop M. et al. Cancer Research in the United States: A Critical Review of Current Status and Proposal for Alternative Models. Cancer. 124, no. 14 (2018): 2881–2889.

Carrera P. M. et al. The Financial Burden and Distress of Patients with Cancer: Understanding and Stepping-Up Action on the Financial Toxicity of Cancer Treatment. CA, January 16, 2018. doi:10.3322/caac.21443.

Fojo T. et al. Unintended Consequences of Expensive Cancer Therapeutics – The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. JAMA Otolaryngology – Head & Neck Surgery. 140, no. 12 (2014): 1225–1236.

Krummel M. F., Allison J. P. CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation. Journal of Experimental Medicine. 182, no. 2 (1995): 459–465.

Davis D. M. The Rise of Cancer Immunotherapy: How Jim Allison Saved a Whole World. Nautilus, October 25, 2018.

Hutchinson L., Kirk R. High Drug Attrition Rates – Where Are We Going Wrong? Nature Reviews Clinical Oncology. 8, no. 4 (2011): 189–190.

Begley G. C., Ellis L. M. Raise Standards for Preclinical Cancer Research. Nature. 483 (2012): 531–533.

Johnson G. The Cancer Chronicles: Unlocking Medicine’s Deepest Mystery. New York: Alfred A. Knopf, 2013.

Yong Ed. How to Fight Cancer When Cancer Fights Back. Atlantic, April 26, 2017.

Gilligan A. M. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer. American Journal of Medicine. 131, no. 10 (2018): 1187–1199.

Baker M. 1,500 Scientists Lift the Lid on Reproducibility: Survey Sheds Light on the “Crisis” Rocking Research. Nature. 533 (2016): 452–454.

Cohen J. D. et al. Combined Circulating Tumor DNA and Protein Biomarker-Based Liquid Biopsy for the Earlier Detection of Pancreatic Cancers. PNAS. 114, no. 38 (2017): 10202–10207.

Wang Y. et al. Detection of Tumor-Derived DNA in Cerebrospinal Fluid of Patients with Primary Tumors of the Brain and Spinal Cord. PNAS. 112, no. 31 (2015): 9704–9709.

Bettegowda C. Detection of Circulating Tumor DNA in Early – and Late-Stage Human Malignancies. Science Translational Medicine. 6, no. 224 (2014): 224ra24.

Vogelstein B. et al. Cancer Genome Landscapes. Science. 339, no. 6127 (2013): 1546–1558.

At the Forefront of Cancer Genetics, Bert Vogelstein, MD, Calls for Focus on Early Detection and Prevention. ASCO Post, June 3, 2017. https://ascopost.com/issues/june-3–2017-narratives-special-issue/at-the-forefront-of-cancer-genetics-bert-vogelstein-md-calls-for-focus-on-early-detection-and-prevention

DeVita V. T., Jr., DeVita-Raeburn E. The Death of Cancer. New York: Sarah Crichton Books, 2015.

Ehrenreich B. Natural Causes: An Epidemic of Wellness, the Certainty of Dying, and Killing Ourselves to Live Longer. New York: Twelve, 2018.

Sullivan Th. A Tough Road: Cost to Develop One New Drug Is $ 2.6 Billion; Approval Rate for Drugs Entering Clinical Development Is Less Than 12 %. Policy and Medicine. www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html

DiMasi J. et al. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 47 (2016): 20–33.

Wong C. H. et al. Estimation of Clinical Trial Success Rates and Related Parameters. Biostatistics. 20, no. 2 (2019): 273–286.

Kim Ch., Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival. JAMA Internal Medicine. 175, no. 12 (2015): 1992–1994.

Maeda H., Khatami M. Analyses of Repeated Failures in Cancer Therapy for Solid Tumors: Poor Tumor-Selective Drug Delivery, Low Therapeutic Efficacy and Unsustainable Costs. Clinical and Translational Medicine. 7, no. 1 (2018): 11.

Kumar H. et al. An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials. JAMA Oncology. 2, no. 9 (2016): 1238–1240.

Thomas D. W. et al. Clinical Development Success Rates, 2006–2015. www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006–2015 %20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

Philippidis A. Unlucky 13: Top Clinical Trial Failures in 2017. Genetic Engineering & Biotechnology News. www.genengnews.com/a-lists/unlucky-13-top-clinical-trial-failures-of-2017/

Szabo L. Dozens of New Cancer Drugs Do Little to Improve Survival, Frustrating Patients. https://khn.org/news/dozens-of-new-cancer-drugs-do-little-to-improve-survival-frustrating-patients/

Rupp T., Zuckerman D. Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints. JAMA Internal Medicine. 177, no. 2 (2017): 276–277.

Davis C. et al. Availability of Evidence on Overall Survival and Quality of Life Benefits of Cancer Drugs Approved by the European Medicines Agency: Retrospective Cohort Study of Drug Approvals from 2009–2013. BMJ. (2017): 359.

Hall S. S. A Commotion in the Blood: Life, Death, and the Immune System. New York: Henry Holt, 1997.

Sandomi R. Julie Yip-Williams, Writer of Candid Blog on Cancer, Dies at 42. New York Times,